Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Core Insights - Bluejay Diagnostics, Inc. reported financial results for Q2 2025 and provided updates on its Symphony IL-6 test program and operational milestones [1][2] Financial Results - The company raised gross proceeds of $3.85 million through warrant inducement financing in April 2025 [5] - Additional capital is anticipated to be required through 2027 to support manufacturing readiness, clinical trials, and regulatory activities [5] Symphony IL-6 Test Program - The Symphony IL-6 Test is designed for sepsis triage and monitoring, providing results in approximately 20 minutes [6] - The SYMON-II pivotal clinical trial has commenced patient enrollment, aiming to validate findings from the SYMON-I pilot study [5] - The SYMON-II study will assess the predictive performance of IL-6 levels in ICU patients for 28-day all-cause mortality [5] Strategic Partnerships and Manufacturing - Bluejay has amended its licensing agreement with Toray Industries, extending the timeline for alternate cartridge manufacturing to October 2026 [5] - The company is collaborating with SanyoSeiko as its contract manufacturing organization to ensure regulatory-grade supply chain readiness [5] Upcoming Catalysts - The company is focused on accelerating patient enrollment and interim data review from SYMON-II [5] - Plans for cartridge redevelopment and validation manufacturing are underway, with ongoing discussions for strategic and institutional financing [5]